Skip to main content
Ultragenyx Pharmaceutical Inc. (RARE)
NASDAQ: RARE · Real-Time Price · USD
41.28
+1.28 (3.20%)
Jan 21, 2025, 4:00 PM EST - Market closed

Ultragenyx Pharmaceutical Revenue by Segment
Period Ending Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020
Product
265.30M 230.30M 198.70M 180.40M 157.60M 147.80M 136.40M 118.90M
Product Growth
68.34% 55.82% 45.67% 51.72% 43.01% 48.24% 56.42% 54.42%
Other
257.40M 250.90M 243.80M 253.80M 252.60M 245.10M 237.50M 234.40M
Other Growth
1.90% 2.37% 2.65% 8.28% 13.27% 4.56% -2.86% -14.51%

Revenue by Geography
Period Ending Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020
North America
316.40M 307.30M 297.70M 307.10M 299.00M 298.20M 286.20M 281.00M
North America Growth
5.82% 3.05% 4.02% 9.29% 11.94% 11.69% 3.96% -6.68%
Latin America
130.30M 109.50M 89.70M 77.30M 67.40M 64.30M 57.70M 44.70M
Latin America Growth
93.32% 70.30% 55.46% 72.93% 61.24% 82.67% 110.58% 89.41%
Europe
69.60M 60.40M 54.20M 47.60M 42.70M 38.10M 37.60M 36.40M
Europe Growth
63.00% 58.53% 44.15% 30.77% 28.61% 19.06% 28.77% 36.84%
Japan
6.40M 4.10M - 2.20M - - 2.40M -
Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.